魯力,謝敏,熊治國
腹腔鏡胃癌根治術(shù)后患者炎癥因子及凝血功能變化的研究
魯力,謝敏,熊治國△
目的探討腹腔鏡胃癌根治術(shù)后患者炎癥因子及凝血功能的變化。方法回顧性分析2012年6月—2014年6月在我院行胃癌治療的77例患者,其中38例予以腹腔鏡治療(腹腔鏡組),39例予以常規(guī)開腹治療(開腹組)。分析比較2組患者術(shù)前、術(shù)后6 h、術(shù)后24 h的白介素(IL)-6、IL-8、腫瘤壞死因子-α(TNF-α)、血清活化部分凝血活酶時間(APTT)、凝血酶原時間(PT)、國際標準化比值(INR)、纖維蛋白原(FIB)、D二聚體(D-D)的水平變化情況;統(tǒng)計并比較2組患者術(shù)后血栓發(fā)生例數(shù)及腫瘤復發(fā)情況。結(jié)果2組患者在性別、年齡、腫瘤大小、分化程度及TNM分期上的差異均無統(tǒng)計學意義,具有可比性。術(shù)后2組患者血清IL-6、IL-8、TNF-α水平與術(shù)前相比均明顯升高(P<0.01),且開腹組高于腹腔鏡組(P<0.01)。術(shù)后2組患者APTT、PT、INR水平較術(shù)前明顯降低,且腹腔鏡組低于開腹組(P<0.05);2組患者術(shù)后FIB、D-D水平較術(shù)前明顯升高(P<0.05),且腹腔鏡組高于開腹組(P<0.05);腹腔鏡組患者術(shù)后腫瘤復發(fā)例數(shù)少于開腹組,但術(shù)后血栓性疾病發(fā)生例數(shù)則多于開腹組。結(jié)論腹腔鏡胃癌根治術(shù)后患者炎癥介質(zhì)釋放減少,對機體的免疫功能影響較小,但其對患者的凝血功能影響較大,臨床治療時應加以注意。
胃腫瘤;腹腔鏡檢查;開腹手術(shù);胃癌根治術(shù);炎癥因子;凝血功能
近年來,隨著腹腔鏡技術(shù)越來越多地應用于臨床,有關(guān)腹腔鏡術(shù)后患者下肢深靜脈血栓以及肺栓塞的報道也相繼增加,而血栓性疾病又是手術(shù)后較為嚴重的并發(fā)癥之一,如發(fā)現(xiàn)和處理不及時,可能會危及患者的生命[1]。同時手術(shù)創(chuàng)傷對機體免疫功能也會產(chǎn)生一定的影響,而術(shù)后腫瘤的復發(fā)、擴散與機體的免疫功能有著緊密的聯(lián)系[2]。本研究著重觀察腹腔鏡胃癌根治術(shù)對患者免疫功能以及凝血功能的影響,現(xiàn)報告如下。
1.1一般資料回顧性分析2012年6月—2014年6月在我院行胃癌根治術(shù)的77例患者,其中38例行腹腔鏡治療(腹腔鏡組),39例行常規(guī)開腹治療(開腹組),所有患者經(jīng)胃鏡檢查和病理學診斷均為原發(fā)性胃癌。2組患者在性別、年齡、腫瘤大小、分化程度及TNM分期方面差異均無統(tǒng)計學意義,見表1。
Tab.1 Comparison of the general data between two groups of patients表1 2組患者一般資料比較
1.2手術(shù)方法腹腔鏡組:患者仰臥取人字位,常規(guī)氣管插管全麻后臍下置入10 mm Troca作為觀察孔,左側(cè)肋緣下置入12 mm Troca作為主操作孔,左、右腹中部及右肋緣下各放置5 mm Troca作為輔助操作孔,建立CO2氣腹并維持壓力為12 mmHg(1 mmHg=0.133 kPa)。游離胃結(jié)腸韌帶,依次離斷胃網(wǎng)膜左動靜脈、胃短血管;處理胃大彎側(cè)至遠側(cè)切斷線處,游離胃胰粘連,依次離斷胃網(wǎng)膜右動靜脈、胃右動脈、胃左動靜脈;游離完肝胃韌帶后于上腹部近臍處做一5 cm左右切口后常規(guī)行空腸食管吻合,觀察腹腔無活動性出血,放置引流管后關(guān)腹。開腹組:依據(jù)常規(guī)手術(shù)方法進行。
1.3觀察指標炎癥因子指標方面采用ELISA試劑盒(上海酶聯(lián)生物科技有限公司)檢測2組患者術(shù)前、術(shù)后6 h、術(shù)后24 h的血清白細胞介素(IL)-6、IL-8、腫瘤壞死因子(TNF)-α及D二聚體(D-D)。凝血指標方面采用BECKMAN全自動血凝儀(美國貝克曼庫爾特公司)測定2組患者術(shù)前、術(shù)后6 h、術(shù)后24 h血清活化部分凝血活酶時間(APTT)、凝血酶原時間(PT)及纖維蛋白原(FIB)水平,并采取國際標準化比值(INR)法進行計算INR,并統(tǒng)計2組患者術(shù)后血栓發(fā)生例數(shù)及腫瘤復發(fā)情況。
1.4統(tǒng)計學方法采用SPSS 17.0軟件進行數(shù)據(jù)分析,2組計量資料用均數(shù)±標準差(±s)表示,組間比較采用t檢驗,組內(nèi)不同時點比較采用重復測量數(shù)據(jù)的方差分析,計數(shù)資料比較采用卡方檢驗,P<0.05為差異有統(tǒng)計學意義。
2.12組患者術(shù)前及術(shù)后炎癥因子指標變化比較2組患者術(shù)前血清IL-6、IL-8、TNF-α水平無明顯差異(P>0.05)。術(shù)后2組患者血清IL-6、IL-8、TNF-α水平均較術(shù)前明顯升高(P<0.01),且開腹組高于腹腔鏡組(均P<0.01),見表2。
Tab.2 Comparison of the inflammatory factor index before and after operation between two groups of patients表2 2組患者術(shù)前及術(shù)后炎癥因子指標變化情況比較(ng/L,±s)
Tab.2 Comparison of the inflammatory factor index before and after operation between two groups of patients表2 2組患者術(shù)前及術(shù)后炎癥因子指標變化情況比較(ng/L,±s)
*P<0.05,**P<0.01;表3同
組別腹腔鏡組開腹組t F組間/F組內(nèi)/F交互n 38 39 IL-6術(shù)前3.44±1.78 3.29±1.71 0.377 244.274**/983.401**/71.454**術(shù)后6 h 24.42±5.24 34.53±5.43 8.317*術(shù)后24 h 8.62±2.58 21.97±3.51 18.972*組別腹腔鏡組開腹組t F組間/F組內(nèi)/F交互n 38 39 IL-8術(shù)前2.57±1.62 2.63±1.31 0.175 115.432**/1 225.173**/57.260**術(shù)后6 h 25.74±5.25 38.41±6.47 9.421*術(shù)后24 h 17.23±2.41 21.75±2.87 7.471*組別腹腔鏡組開腹組t F組間/F組內(nèi)/F交互n 38 39 TNF-α術(shù)前117.60±23.35 119.15±19.88 0.314 27.729**/124.221**/8.803**術(shù)后6 h 160.94±21.58 191.11±17.65 6.723*術(shù)后24 h 139.87±35.11 165.80±26.17 3.681*
2.22組患者術(shù)前及術(shù)后凝血纖溶指標的變化比較2組患者術(shù)前APTT、PT、INR、FIB、D-D水平無明顯差異(P>0.05)。術(shù)后2組患者APTT、PT、INR水平較術(shù)前明顯降低,且腹腔鏡組低于開腹組(均P<0.05);2組患者術(shù)后FIB、D-D水平則較術(shù)前明顯升高(P<0.05),且腹腔鏡組高于開腹組(均P<0.05),見表3。
2.32組患者術(shù)后血栓性疾病及腫瘤復發(fā)情況比較開腹組1例出現(xiàn)術(shù)后下肢深靜脈血栓,而腹腔鏡組中術(shù)后發(fā)生下肢輕度深靜脈血栓7例,2組之間差異有統(tǒng)計學意義(χ2=5.198,P<0.05);隨訪2組術(shù)后1年腫瘤復發(fā)情況,腹腔鏡組隨訪35例,失訪3例,開腹組隨訪33例,失訪6例,腹腔鏡組3例患者出現(xiàn)腫瘤復發(fā),而開腹組中則有10例患者出現(xiàn)腫瘤復發(fā),2組之間差異有統(tǒng)計學意義(χ2=4.320,P<0.05)。
Tab.3 Comparison of blood coagulation and fibrinolysis indexes before and after operation between two groups of patients表3 2組患者術(shù)前及術(shù)后凝血纖溶指標的變化情況比較(±s)
Tab.3 Comparison of blood coagulation and fibrinolysis indexes before and after operation between two groups of patients表3 2組患者術(shù)前及術(shù)后凝血纖溶指標的變化情況比較(±s)
組別腹腔鏡組開腹組t F組間/F組內(nèi)/F交互n 38 39 APTT(s)術(shù)前29.75±3.26 29.88±3.48 0.163 5.681*/6.272**/1.064術(shù)后6 h 28.15±2.94 29.61±3.19 2.085*術(shù)后24 h 27.57±2.14 28.70±2.32 2.224*PT(s)術(shù)前12.84±0.83 12.78±0.85 0.298 8.499**/12.933**/2.503術(shù)后6 h 11.88±2.04 12.69±0.90 2.246*術(shù)后24 h 11.55±0.92 12.07±1.10 2.284*組別腹腔鏡組開腹組t F組間/F組內(nèi)/F交互n 38 39 INR術(shù)前1.02±0.14 1.03±0.12 0.392 9.655**/6.254**/1.902術(shù)后6 h 0.93±0.14 1.01±0.14 2.709*術(shù)后24 h 0.91±0.13 0.99±0.15 2.57*FIB(g/L)術(shù)前2.32±0.60 2.23±0.63 0.652 15.990**/172.916**/2.520術(shù)后6 h 3.25±0.44 2.90±0.47 3.423*術(shù)后24 h 3.98±0.45 3.54±0.50 4.042**組別腹腔鏡組開腹組t F組間/F組內(nèi)/F交互n D-D(μg/L)38 39術(shù)前142.91±33.65 137.45±28.11 0.773術(shù)后6 h 243.33±52.57 223.42±25.41 2.124*26.963**/430.481**/3.670*術(shù)后24 h 346.99±35.80 307.17±41.03 4.534**
外科手術(shù)是治療胃癌的主要方法,但手術(shù)創(chuàng)傷在一定程度上會導致術(shù)后機體的免疫抑制,其抑制程度與創(chuàng)傷的嚴重程度相關(guān)。有研究顯示[3],由手術(shù)創(chuàng)傷而介導的免疫抑制可能會增加術(shù)后感染和腫瘤擴散的概率,且手術(shù)創(chuàng)傷對機體的凝血功能也有著一定的影響[4],因此研究不同的手術(shù)方式對于胃癌患者免疫和凝血功能的影響有著重要的意義。
IL-6在手術(shù)創(chuàng)傷早期即可表達,是組織損傷的敏感指標之一,與手術(shù)的創(chuàng)傷程度相關(guān),其濃度的升高可以直接反映出創(chuàng)傷對機體造成的損害。IL-8可促進中性粒細胞脫顆粒,釋放彈性蛋白酶,損傷內(nèi)皮細胞,使微循環(huán)血流淤滯,組織壞死,造成器官功能損傷,進而增加患者術(shù)后感染的概率。TNF-α是炎癥反應過程中出現(xiàn)最早、最重要的炎性介質(zhì),能激活中性粒細胞和淋巴細胞,使血管內(nèi)皮細胞通透性增加,調(diào)節(jié)其他組織代謝活性并促使其他細胞因子的合成和釋放,對機體的免疫反應起到抑制作用。綜上,外周血中IL-6、IL-8、TNF-α水平在術(shù)后早期即可增高,且與創(chuàng)傷的嚴重程度呈正性相關(guān),在一定程度上反映手術(shù)創(chuàng)傷對機體免疫功能的抑制程度[5-6]。所以,減少術(shù)后IL-6、IL-8、TNF-α的釋放,對胃癌患者術(shù)后的恢復具有積極的作用。本研究結(jié)果顯示術(shù)后兩組患者血清IL-6、IL-8、TNF-α水平與術(shù)前相比均明顯升高,但腹腔鏡組明顯低于開腹組,可見2種手術(shù)方式均會引起機體的炎癥反應,在一定程度上抑制患者的免疫功能,但腹腔鏡手術(shù)對機體的創(chuàng)傷更小,術(shù)后機體應激反應程度更輕,對機體免疫功能抑制更小,本研究術(shù)后2組患者腫瘤復發(fā)情況亦進一步說明這一點。
雖然腹腔鏡手術(shù)對機體的創(chuàng)傷更小,術(shù)后機體的炎癥反應更輕,但其對患者的凝血功能影響卻較大。APTT主要反映內(nèi)源性凝血系統(tǒng)狀況,降低見于高凝狀態(tài),如促凝物質(zhì)進入血液及凝血因子的活性增高等情況。PT主要反映外源性凝血系統(tǒng)狀況,縮短見于血液高凝狀態(tài)和血栓性疾病等。FIB主要反映纖維蛋白原的含量,D-D主要反映纖維蛋白溶解功能,增高或陽性見于繼發(fā)性纖維蛋白溶解功能亢進,它們均能較為準確地反映機體凝血功能的變化[7]。本研究結(jié)果顯示腹腔鏡術(shù)后6 h及術(shù)后24 h 的APTT、PT及INR水平較開腹組降低,F(xiàn)IB、D-D水平較開腹組升高,這反映出腹腔鏡組患者術(shù)后血液凝固性高于開腹組,本研究結(jié)果部分2組患者術(shù)后血栓性疾病的發(fā)生例數(shù)與此結(jié)論相符合。腹腔鏡組血液凝固性較高的原因可能為腹腔鏡手術(shù)時CO2氣腹對腹腔血管的影響,手術(shù)操作中長時間的頭高腳低位,以及因腹腔鏡下分離血管、清掃淋巴結(jié)等操作困難導致手術(shù)時間延長造成靜脈血液瘀滯,增加了激活的血小板和凝血因子與靜脈壁接觸的時間,容易引起血栓形成,是下肢深靜脈血栓形成的首要因素[8]。因此,在腹腔鏡手術(shù)治療時應對患者血液高凝狀態(tài)予以注意。
綜上,腹腔鏡胃癌根治術(shù)具有創(chuàng)傷小、恢復快、術(shù)后機體應激反應程度輕及對機體的免疫功能影響小等優(yōu)點,但其對患者凝血系統(tǒng)的影響較大。因此,在胃癌患者腹腔鏡手術(shù)治療時,應做好全面的評估,并采取相應的措施,預防高凝狀態(tài)的出現(xiàn),努力避免患者術(shù)后深靜脈血栓的形成。
[1]De Martino RR,Goodney PP,Spangler EL,et al.Variation in thromboembolic complications among patients undergoing commonly performed cancer operations[J].J Vasc Surg,2012,55(4):1035-1040.
[2]Finn OJ.Immuno-oncology:understanding the function and dysfunction of the immune system in cancer[J].Ann Oncol,2012,23(Suppl 8):viii6-9.
[3]Chopra SS,Haacke N,Meisel C,et al.Postoperative immunosuppression after open and laparoscopic liver resection:assessment of cellular immune function andmonoc-Ytic HLA-DR expression[J]. JSLS,2013,17(4):615-621.
[4]Weinberg L,Scurrah N,Parker FC,et al.Markers of coagulation activation after hepatic resection for cancer:evidence of sustained upregulation of coagulation[J].Anaesth Intensive Care,2011,39(5): 847-853.
[5]Watanabe T,Takahashi A,Suzuki K,et al.Epithelial-mesenchymal transition in human gastric cancer cell lines induced by TNF-a-inducing protein of Helicobacter pylori[J].Int J Cancer,2014,134(10): 2373-2382.
[6]Ruzzo A,Catalano V,Canestrari E,et al.Genetic modulation of the interleukin 6(IL-6)system in patients with advanced gastric cancer:a background for an alternative target therapy[J].BMC Cancer,2014,14(1):357.
[7]Ma X,Li Y,Zhang J,et al.Prognostic role of D-dimer in patients with lung cancer:a meta-analysis[J].Tumour Biol,2014,35(3): 2103-2109.
[8]HuangZP,LiuXJ,ZouBX,etal.The complete recanalization of PICC-related ve-nous thrombosis in cancer patients:A series of case reports[J].Exp Ther Med,2013,6(2):411-412.
(2014-07-09收稿2014-08-29修回)
(本文編輯李國琪)
Researches on inflammatory factor and blood coagulation in patients with laparoscopic gastric cancer radical surgery
LU Li,XIE Min,XIONG Zhiguo△
Hubei Cancer Hospital,Wuhan 430071,China
△Corresponding AuthorE-mail:1790946193@qq.com
ObjectiveTo investigate the change of inflammatory factor and blood coagulation in patients with laparoscopic gastric cancer radical surgery.MethodsData of seventy-seven stomach cancer patients hospitalized in our hospital and received the surgical treatment from June 2012 to June 2014 were retrospectively analyzed.Thirty-eight of these patients underwent laparoscopic treatment(laparoscopic group)and 39 cases received laparotomy treatment(laparotomy group). The values of interleukin-6(IL-6),IL-8 and tumor necrosis factor alpha(TNF-α)were analyzed at the time points of preoperation and 6 h,24 h after the surgery in two groups.The levels of activated partial thromboplastin time(APTT),prothrombin time(PT),international standardization ration(INR),fibrinogen(FIB)and D dimer(D-D)were also analyzed at the same time points in two groups.The postoperative thrombosis and tumor recurrence rate were also analyzed in two groups of patients.ResultsThere were no significant differences in the gender,age,the size of tumor,differentiation degree and TNM staging between two groups of patients.The serum levels of IL-6,IL-8 and TNF-α were significantly increased after surgery in two groups(P<0.01),and which were significantly higher in laparotomy group than those of laparoscopic group(P<0.01).The levels of APTT,PT and INR were significantly lower after surgery in two groups of patients,and which were significantly lower in laparoscopic group than those of laparotomy group(P<0.05).The levels of FIB and D-D were significantly increased after operation in two groups of patients(P<0.05),which were significantly higher in laparoscopic group than those of laparotomy group(P<0.05).The postoperative recurrence of cancer was less in laparoscopic group than that of laparotomy group.But,the postoperative thrombosis was more in laparoscopic group than that of laparotomy group.Conclusion There was less release of inflammatory mediators and less effect on the body's immune function in patients with laparoscopic gastric cancer radical surgery.But,the surgery has a large influence in blood coagulation,we should pay attention to it in the clinical treatment.
stomach neoplasms;laparoscopy;laparotomy;gastric cancer radical gastrectomy;inflammatory factor;blood coagulation function
R735.2
ADOI:10.11958/j.issn.0253-9896.2015.03.014
湖北省自然科學基金資助項目(2013CFC023)
武漢,湖北省腫瘤醫(yī)院胃腸外科(郵編430071)
魯力(1978),男,博士,主要從事消化道腫瘤研究
△E-mail:1790946193@qq.com